The techniques and patents provide significant protection for InNexus’s latest scientific achievement and growing product pipeline.
Thomas Kindt, chief scientific officer of InNexus, said: “The DXLmouse is another R&D tool that enables InNexus to target a desirable antibody, introduce the antibody into the mouse and then have that animal produce the desired antibody incorporating InNexus’s Dynamic Cross Linking technology. Each mouse represents a ‘DXL antibody factory’ which combines the power of natural antibody diversity generation with the augmented potency of DXL technology.”